Literature DB >> 20963564

Relationship between RANKL and neuroendocrine activation in elderly males with heart failure.

Goran Loncar1, Biljana Bozic, Vojkan Cvorovic, Zoran Radojicic, Sinisa Dimkovic, Natasa Markovic, Nenad Prodanovic, Toplica Lepic, Biljana Putnikovic, Vera Popovic-Brkic.   

Abstract

The main cytokines regulating bone remodeling are the receptor activator of nuclear factor-κB ligand (RANKL) and its decoy receptor, osteoprotegerin (OPG). Recent data have linked RANKL and OPG to cardiovascular disease as well. NT-pro-BNP and adiponectin are well-established biomarkers of heart failure reflecting neuroendocrine activation in this multi-complex disorder. The objective of this article was to investigate whether RANKL is associated with neuroendocrine activation in 75 elderly males with mild to moderate congestive heart failure (CHF) and left ventricular ejection fraction <40%. The control group consisted of 20 healthy male volunteers with matching age and body mass index (BMI). Serum RANKL (sRANKL), OPG, NT-pro-BNP, adiponectin, leptin, clinical, and echocardiography parameters were evaluated. In comparison to the control group, the CHF patients showed significantly increased sRANKL levels [126.8 (122.6) vs. 47.8 (44.4) pg/ml, P < 0.0001]. There was a significant relative risk of systolic CHF in elderly males associated with increased sRANKL above the calculated cut-off of 83 pg/ml [OR = 10.286 (95%CI 3.079-34.356), P < 0.0001; RR = 3.600 (95%CI = 1.482-8.747)]. In the CHF patients, the log-transformed values of sRANKL levels correlated positively with the log-transformed values of the serum NT-pro-BNP and adiponectin levels (P = 0.004, r = 0.326 and P = 0.037, r = 0. 241, respectively), while inversely correlated with the BMI and creatinine clearance (P = 0.015, r = -0.281 and P = 0.042, r = -0.236, respectively). In multivariate regression model, sRANKL was a significant determinant of NT-pro-BNP independent of age, BMI and creatinine clearance (P = 0.002, R (2) = 0.546). In conclusion, our study suggests that in elderly males with systolic heart failure sRANKL was significantly associated with parameters of neuroendocrine activation such as NT-pro-BNP and adiponectin. Further studies are needed to elucidate the potential role of sRANKL in the complex pathogenesis of heart failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20963564     DOI: 10.1007/s12020-009-9282-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  33 in total

Review 1.  Osteoprotegerin ligand: a regulator of immune responses and bone physiology.

Authors:  Y Y Kong; W J Boyle; J M Penninger
Journal:  Immunol Today       Date:  2000-10

2.  ATS statement: guidelines for the six-minute walk test.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

3.  Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure.

Authors:  Caroline Kistorp; Jens Faber; Søren Galatius; Finn Gustafsson; Jan Frystyk; Allan Flyvbjerg; Per Hildebrandt
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

4.  Circulating adiponectin concentrations in patients with congestive heart failure.

Authors:  J George; S Patal; D Wexler; Y Sharabi; E Peleg; Y Kamari; E Grossman; D Sheps; G Keren; A Roth
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

Review 5.  Cardioprotection by adiponectin.

Authors:  Noriyuki Ouchi; Rei Shibata; Kenneth Walsh
Journal:  Trends Cardiovasc Med       Date:  2006-07       Impact factor: 6.677

6.  Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.

Authors:  Thor Ueland; Arne Yndestad; Erik Øie; Geir Florholmen; Bente Halvorsen; Stig S Frøland; Svein Simonsen; Geir Christensen; Lars Gullestad; Pål Aukrust
Journal:  Circulation       Date:  2005-05-09       Impact factor: 29.690

7.  Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Yoshihisa Okamoto; Shinji Kihara; Noriyuki Ouchi; Makoto Nishida; Yukio Arita; Masahiro Kumada; Koji Ohashi; Naohiko Sakai; Iichiro Shimomura; Hideki Kobayashi; Naoki Terasaka; Toshimori Inaba; Tohru Funahashi; Yuji Matsuzawa
Journal:  Circulation       Date:  2002-11-26       Impact factor: 29.690

8.  Serum adiponectin level as an independent predictor of mortality in patients with congestive heart failure.

Authors:  Toshihiro Tamura; Yutaka Furukawa; Ryoji Taniguchi; Yukihito Sato; Koh Ono; Hisanori Horiuchi; Yoshihisa Nakagawa; Toru Kita; Takeshi Kimura
Journal:  Circ J       Date:  2007-05       Impact factor: 2.993

9.  Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction.

Authors:  Thor Ueland; Rune Jemtland; Kristin Godang; John Kjekshus; Aina Hognestad; Torbjørn Omland; Iain B Squire; Lars Gullestad; Jens Bollerslev; Kenneth Dickstein; Pål Aukrust
Journal:  J Am Coll Cardiol       Date:  2004-11-16       Impact factor: 24.094

10.  Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system.

Authors:  G S Filippatos; K Tsilias; K Venetsanou; E Karambinos; D Manolatos; A Kranidis; J Antonellis; F Kardaras; L Anthopoulos; G Baltopoulos
Journal:  Int J Cardiol       Date:  2000 Nov-Dec       Impact factor: 4.164

View more
  8 in total

Review 1.  Heart failure management in the elderly - a public health challenge.

Authors:  Natasa Cvetinovic; Goran Loncar; Jerneja Farkas
Journal:  Wien Klin Wochenschr       Date:  2016-11-29       Impact factor: 1.704

2.  Enhanced mineralization potential of vascular cells from SM22α-Rankl (tg) mice.

Authors:  S Morony; A P Sage; T Corbin; J Lu; Y Tintut; L L Demer
Journal:  Calcif Tissue Int       Date:  2012-10-09       Impact factor: 4.333

Review 3.  The role of OPG/RANKL in the pathogenesis of diabetic cardiovascular disease.

Authors:  Hannah Forde; Colin Davenport; Emma Harper; Phil Cummins; Diarmuid Smith
Journal:  Cardiovasc Endocrinol Metab       Date:  2018-05-16

Review 4.  Diagnosing destabilized heart failure in the emergency setting: current and future biomarker tests.

Authors:  Damien Gruson; Frédéric Thys; Franck Verschuren
Journal:  Mol Diagn Ther       Date:  2011-12-01       Impact factor: 4.074

5.  Gene polymorphisms and thyroid function in patients with heart failure.

Authors:  Ioannis Vasiliadis; Genovefa Kolovou; Vana Kolovou; Vasiliki Giannakopoulou; Maria Boutsikou; Niki Katsiki; Evaggelia Papadopoulou; Sophie Mavrogeni; Konstantina Sorontila; Costas Pantos; Dennis V Cokkinos
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

6.  Inverse Regulation of Serum Osteoprotegerin and B-Type Natriuretic Peptide Concentrations by Free Fatty Acids Elevation in Young Healthy Humans.

Authors:  Marta Dobrzycka; Adrian Kołakowski; Magdalena Stefanowicz; Natalia Matulewicz; Agnieszka Nikołajuk; Monika Karczewska-Kupczewska
Journal:  Nutrients       Date:  2022-02-17       Impact factor: 5.717

7.  Relationship between bone mineral density and serum osteoprotegerin in patients with chronic heart failure.

Authors:  Ying-Hsien Chen; Yen-Wen Wu; Wei-Shiung Yang; Shoei-Shen Wang; Chi-Ming Lee; Nai-Kuan Chou; Ron-Bin Hsu; Yen-Hung Lin; Mao-Shin Lin; Yi-Lwun Ho; Ming-Fong Chen
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

Review 8.  Bone in heart failure.

Authors:  Goran Loncar; Natasa Cvetinovic; Mitja Lainscak; Andjelka Isaković; Stephan von Haehling
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-02-22       Impact factor: 12.910

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.